Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGS2 | P35354 | 9/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | TDP2 | O95551 | 1/20 | 0.38 |
| ▸ | BRD4 | O60885 | 1/20 | 0.35 |
| ▸ | GSK3B | P49841 | 4/20 | 0.35 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.35 |
| ▸ | WEE1 | P30291 | 1/20 | 0.35 |
| ▸ | GSK3A | P49840 | 1/20 | 0.33 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | CA12 | O43570 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.32 |
| ▸ | CA2 | P00918 | 1/20 | 0.32 |
| ▸ | CA9 | Q16790 | 1/20 | 0.32 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10694749 | 0.79 | PTGS2 (0.56) | PTGS2ALDH1A1GSK3BHSD17B10 | |
| SCHEMBL3791544 | 0.76 | PTGS2 (0.46) | PTGS2CYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL29042770 | 0.76 | KIF11 (0.42) | PTGS2TDP2 | |
| SCHEMBL27936511 | 0.73 | PTGS2 (0.48) | PTGS2GSK3B | |
| SCHEMBL21764396 | 0.72 | CYP3A4 (0.43) | PTGS2CYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL30585016 | 0.72 | PTGS2 (0.39) | PTGS2CYP3A4TDP1ALDH1A1TP53 | |
| SCHEMBL4195826 | 0.65 | ALDH1A1 (0.69) | CYP3A4TDP1ALDH1A1TP53TAAR1 | |
| SCHEMBL22409597 | 0.64 | CYP3A4 (0.50) | CYP3A4TDP1ALDH1A1TP53BRD4 | |
| SCHEMBL29024801 | 0.64 | ACHE (0.46) | CYP3A4TDP1ALDH1A1TP53TDP2 | |
| SCHEMBL7193397 | 0.63 | PTGS2 (0.48) | PTGS2GSK3B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | BERGER MARKUS | 2008-07-10 | — | — | US | claimed |
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | BERGER MARKUS | 2008-07-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080166362-A1 | New effector conjugates, process for their production and their pharmaceutical use | EPOR, TIE1, TEK | PTGS2 1116/4885CYP3A4 1817/4885TDP1 4191/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.